Publications by authors named "Roland Fuchs"

Claim this Profile
N
Novel homozygous nonsense mutation in the P5'N-1 coding gene as an alternative cause for hereditary anemia with basophilic stippling.
Martin Kirschner, Inga Rebecca Heinen, Steffen Koschmieder, Licinio Manco, Celeste Bento, Roland Fuchs

Clin Case Rep· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Christian Michel, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Andreas Neubauer, Roland Fuchs

Haematologica· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Platelets - what should a GP know about].
Roland Fuchs

MMW Fortschr Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cup-like blasts in acute myeloid leukemia.
Edgar Jost, Reinhild Herwartz, Mareike Hoß, Lucia Vankann, Roland Fuchs

Am J Hematol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Christoph Roderburg, Nicole do O, Roland Fuchs, Jhenee Bubenzer, Michael Spannbauer

Clin Colorectal Cancer· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Carsten Zwick, Josef Birkmann, Norma Peter, Heinrich Bodenstein, Roland Fuchs

Ann Hematol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Wolfgang Hiddemann, Michael Kneba, Martin Dreyling, Norbert Schmitz, Eva Lengfelder, Roland Fuchs

Blood· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis